The purpose of present study was to experimentally evaluate the dosimetric uncertainties in 3-dimensional conformal radiotherapy (3DCRT), dynamic intensity modulated radiotherapy (D-IMRT), step-shoot (SS-IMRT), and volumetric modulated arc therapy (VMAT) treatment delivery techniques due to intra-and inter-fractional target motion. Methods: A previously treated lung patient was selected for this study and was replanned for 60 Gy in 30 fractions using four techniques (3DCRT, D-IMRT, SS-IMRT, and VMAT). These plans were delivered in a clinical linear accelerator equipped with HexaPOD™ evo RT System. The target dose of static QUASAR phantom was calculated that served as reference dose to the target. The QUASAR respiratory body phantom along with patients breathing wave form and HexaPOD™ evo RT System was used to simulate the intra-fraction and inter-fraction motions. Dose measurements were done by applying the intra-fractional and inter-fractional motions in all the four treatment delivery techniques. Results: The maximum percentage deviation in a single field was-4.3%, 10.4%, and-12.2% for 3DCRT, D-IMRT and SS-IMRT deliveries, respectively. Similarly, the deviation for a single fraction was-1.51%,-1.88%,-2.22%, and-3.03% for 3DCRT, D-IMRT, SS-IMRT and VMAT deliveries, respectively. Conclusion: The impact of inter-fractional and intra-fractional uncertainties calculated as deviation between dynamic and static condition dose was large in some fractions, however average deviation calculated for thirty fractions was well within 0.5% in all the four techniques. Therefore, inter-and intra-fractional uncertainties could be concern in fewer fraction treatments such as stereotactic body radiation therapy, and should be used in conjunction with intra-and inter-fractional motion management techniques.
BackgroundOptically stimulated luminescence dosimeters (OSLDs) have a number of advantages in radiation dosimetry making them an excellent dosimeter for in vivo dosimetry. The study aimed to study the dosimetric characteristics of a commercial optically stimulated luminescence (OSL) system by Landauer Inc., before using it for routine clinical practice for in vivo dosimetry in radiotherapy. Further, this study also aimed to investigate the cause of variability found in the literature in a few dosimetric parameters of carbon-doped aluminium oxide (Al2O3:C).Materials and methodsThe commercial OSLD system uses Al2O3:C nanoDotTM as an active radiation detector and InLightTM microStar® as a readout assembly. Inter-detector response, energy, dose rate, field size and depth dependency of the detector response were evaluated for all available clinical range of photon beam energies in radiotherapy.ResultsInter-detector variation in OSLD response was found within 3·44%. After single light exposure for the OSL readout, detector reading decreased by 0·29% per reading. The dose linearity was investigated between dose range 50–400 cGy. The dose response curve was found to be linear until 250 cGy, after this dose, the dose response curve was found to be supra-linear in nature. OSLD response was found to be energy independent for Co60 to 10 MV photon energies.ConclusionsThe cause of variability found in the literature for some dosimetric characteristics of Al2O3:C is due to the difference in general geometry, construction of dosimeter, geometric condition of irradiation, phantom material and geometry, beam energy. In addition, the irradiation history of detector used and difference in readout methodologies had varying degree of uncertainties in measurements. However, the large surface area of the detector placed in the phantom with sufficient build-up and backscatter irradiated perpendicularly to incident radiation in Co60 beam is a good method of choice for the calibration of a dosimeter. Understanding the OSLD response with all dosimetric parameters may help us in estimation of accurate dose delivered to patient during radiotherapy treatment.
Background: Craniospinal irradiation (CSI) is an important and challenging radiotherapy technique used for the treatment of Medulloblastoma, one of the most common pediatric cancers. Pediatric patients present with wide variability in weight, height, spine length, brain diameter, body size, intra and inter fractional motion depending on their age as compared to adults. These parameters have significant impact on radiation dose delivery to target and normal structures during radiotherapy of pediatric cancer patients. The present study was aimed to evaluate dosimetric parameters and generate plan quality indices for adolescent CSI. Materials and Methods: A 17 years old male adolescent patient with Medulloblastoma was recruited in the present sturdy. The patient was planned with RapidArc TM / Volumetric Modulated Arc Therapy (VMAT) mode using 6 MV X-Ray photon beam from Varian Trilogy with FFF machine. The dose points such as max, mean, 2%, 98%, 95%, 105% and 107% were collected using dose statistics and dose volume histogram (DVH) and analyzed for calculation of various dosimetric parameters. The in-vivo dosimetry was performed and radiation doses to eyes were assessed using CaSO4:Dy TLD powder. Results: The plans were approved with a gamma passing rate (3%, 3mm) of more than 95%. The dose homogeneity index and conformity index were observed 0.074 and 1.10 respectively. The average doses to eyes were observed approximately 35% of the tumor dose during RapidArc TM-CSI. The results of the present study demonstrated that V5 was observed high the normal structures except kidneys. Esophagus and thyroid were receiving significant low dose spillage at a cost of high homogeneity and conformity of dose to PTV which were needed to enhance tumor control probability (TCP) of Medulloblastoma. Conclusion: The present study developed a benchmark guide for adolescent RapidArc TM-CSI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.